Stock Price Movement and Market Context
On 6 Mar 2026, Mercury Laboratories Ltd opened with a gain of 2.49%, reaching an intraday high of Rs.812. However, the stock reversed course during the session, hitting an intraday low of Rs.775, which represents a 2.18% decline from the previous close. This low marks the stock’s weakest level in the past year, down from its 52-week high of Rs.976. The day’s performance saw the stock underperform its Pharmaceuticals & Biotechnology sector by 0.41%, while the broader Sensex index was trading 0.61% lower at 79,526.31 points after opening 356.91 points down.
Mercury Laboratories has not traded on one day out of the last 20, indicating some irregularity in liquidity or trading interest. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, signalling a sustained downward trend over multiple timeframes.
Financial Performance and Valuation Metrics
Despite the recent price decline, Mercury Laboratories reported some positive financial results in December 2025. The company’s Profit After Tax (PAT) for the nine months ended was Rs.3.88 crores, showing an increase compared to previous periods. Quarterly PBDIT reached a high of Rs.2.52 crores, and the operating profit to net sales ratio for the quarter was at its peak of 13.73%, indicating operational efficiency in recent months.
The company’s Return on Equity (ROE) stands at 9%, and it trades at a Price to Book Value ratio of 1.7, suggesting an attractive valuation relative to its peers. Over the past year, while the stock price has declined by 9.71%, Mercury Laboratories’ profits have risen by 26.7%, resulting in a PEG ratio of 0.7. This indicates that earnings growth has outpaced the stock price decline, although this has yet to translate into price appreciation.
While markets shift, this one's charging ahead! This Micro Cap from Aquaculture shows the strongest momentum signals in current conditions. Don't miss out on this ride!
- - Strongest current momentum
- - Market-cycle outperformer
- - Aquaculture sector strength
Long-Term Performance and Market Position
Mercury Laboratories has experienced a subdued growth trajectory over the last five years, with a compound annual growth rate (CAGR) of just 0.14% in operating profits. This slow growth has contributed to the stock’s underperformance relative to broader market indices. Over the past year, the stock has declined by 9.71%, while the Sensex has gained 6.98%. Furthermore, Mercury Laboratories has underperformed the BSE500 index over the last three years, one year, and three months, reflecting persistent challenges in delivering shareholder returns.
The company’s Mojo Score currently stands at 29.0, with a Mojo Grade of Strong Sell, upgraded from a previous Sell rating on 26 Feb 2026. The Market Cap Grade is 4, indicating a relatively modest market capitalisation within its sector. These ratings reflect the stock’s current valuation and performance metrics, signalling caution in the near term.
Shareholding and Trading Characteristics
The majority of Mercury Laboratories’ shares are held by promoters, indicating concentrated ownership. The stock’s trading pattern has been somewhat erratic, with one day of non-trading in the last 20 sessions. This may reflect lower liquidity or investor hesitation amid the recent price volatility.
Sector and Broader Market Environment
The Pharmaceuticals & Biotechnology sector, in which Mercury Laboratories operates, has seen mixed performance recently. Mercury Laboratories’ underperformance relative to its sector peers by 0.41% today adds to the pressure on the stock. The broader market environment, with the Sensex trading below its 50-day moving average but the 50DMA still above the 200DMA, suggests a cautious market sentiment with potential for volatility.
Is Mercury Laboratories Ltd your best bet? SwitchER suggests better alternatives across peers, market caps, and sectors. Discover stocks that could deliver more for your portfolio!
- - Better alternatives suggested
- - Cross-sector comparison
- - Portfolio optimization tool
Summary of Key Metrics
To summarise, Mercury Laboratories Ltd’s stock has reached a 52-week low of Rs.775, reflecting a decline of approximately 20.7% from its 52-week high of Rs.976. The stock’s performance over the last year has been negative at -9.71%, contrasting with the Sensex’s positive 6.98% return. Despite some recent improvements in profitability and operational margins, the company’s long-term growth remains modest, with a 0.14% CAGR in operating profits over five years.
The stock’s valuation metrics, including a Price to Book Value of 1.7 and a PEG ratio of 0.7, suggest that the market is pricing in subdued growth expectations. The Mojo Grade of Strong Sell and a Mojo Score of 29.0 further underline the cautious stance reflected in the stock’s current price action.
Mercury Laboratories continues to face headwinds in regaining upward momentum, as evidenced by its trading below all major moving averages and its underperformance relative to sector peers and broader indices. The concentrated promoter shareholding and occasional erratic trading days add further complexity to the stock’s market behaviour.
Investors monitoring Mercury Laboratories should note the divergence between improving profit metrics and the stock’s price performance, which remains subdued amid broader market pressures and sector dynamics.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
